Provided is the use of an isolated human anti-TNFa antibody, or antigen binding portion thereof, in the manufacture of a medicament for treating erosive polyarthritis in a human subject having psoriatic arthritis, wherein the human anti-TNFa antibody, or an antigen-binding portion thereof, dissociates from human TNFa with a Kd of 1 x 10-8 M or less and a Koff rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon resonance, and neutralizes human TNFa cytotoxicity in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less. Further provided are specific sequences for suitable 6 CDRs in such an antibody.
